Jun 2, 2023 8:30 am EDT Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
May 9, 2023 7:00 am EDT Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
May 1, 2023 7:00 am EDT Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting
Apr 27, 2023 2:55 pm EDT Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind
Apr 26, 2023 7:00 am EDT Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
Apr 21, 2023 7:00 am EDT Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
Apr 17, 2023 7:00 am EDT Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
Mar 30, 2023 7:00 am EDT Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
Mar 23, 2023 7:00 am EDT Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
Mar 10, 2023 7:00 am EST Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting